|
ImmunoGen, Inc. : Announces Activity Reported with SAR3419 Plus Rituxan In …
4-traders (press release) … technology, today announced the presentation of clinical findings with SAR3419 (coltuximab ravtansine) used in combination with Rituxan® (rituximab) to treat diffuse large B-cell lymphoma (DLBCL) that previously had been treated with standard … |
This is Local London |
Obinutuzumab routs rituximab in older chronic lymphocytic leukemia patients
The Oncology Report In the CLL11 study of older chronic lymphocytic leukemia (CLL) patients with coexisting medical problems, obinutuzumab (Gazyva) pushed the overall response rate to 78%, compared with 65% with rituximab (Rituxan) (P less than .0001). Both drugs were … Obinutuzumab Tops Rituximab in CLL TrialCancer Network Dr. Goede on Obinutuzumab Versus Rituximab in CLLOncLive New Drug Combo Potentially ‘Practice Changing’ in CLLMedscape Healio –PR Newswire (press release) all 15 news articles » |
|
Janssen Oncology Data to be Presented at 2013 American Society of …
FiercePharma Combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP): updated results from a phase 1b study in treatment-naïve patients with CD20-positive B-cell non-Hodgkin’s lymphoma (NHL). (Abstract 852). |
|
Interim Phase IIa Results for Spiegelmer ® Olaptesed Pegol (NOX-A12) in CLL …
Business Wire (press release) In the first study, olaptesed was administered to relapsed chronic lymphocytic leukemia (CLL) patients in combination with bendamustine and rituximab. In the second study, olaptesed was combined with bortezomib and dexamethasone in patients with … |
OncLiveObinutuzumab Regimen Slows CLL Compared With Standard TherapyOncLivePatients with chronic lymphocytic leukemia (CLL) and major comorbidities had significantly better outcomes when treated with the anti-CD20 monoclonal antibody obinutuzumab (Gazy…
|
New Drug Combo Potentially ‘Practice Changing’ in CLL
Medscape NEW ORLEANS — More clinical details have been reported showing how the new monoclonal antibody obinutuzumab (Gazvya, Roche) was superior to the stadard therapy rituximab (Rituxan, Roche) when both were used in combination with chlorambucil in … |
Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent …Business Wire (press release)Study 101-09 is a Phase 2, open-label, single-arm efficacy and safety study of idelalisib in patients with previously treated iNHL that is refra…
WalesOnline |
Dr. Goede on Obinutuzumab Versus Rituximab in CLL
OncLive Valentin Goede, MD, from the University Hospital Cologne and the German CLL Study Group, discusses the efficacy findings from the stage 2 CLL11 study that examined obinutuzumab (Gazyva; formally GA101) plus chlorambucil in patients with chronic … New Drug Combo Potentially ‘Practice Changing’ in CLLMedscape Improved Efficacy, Limited Toxicity of Targeted Therapies Brighten the Future …SYS-CON Media (press release) ‘Exciting’ leukaemia drug trial results published after Welsh hospital trialsWalesOnline |
|
Excitement Over CAR-Engineered T-cells in Leukemia and Lymphoma
Medscape This was a patient who had undergone 10 prior therapies, including many different combinations of rituximab plus chemotherapy regimens, and the disease progressed a month after chemotherapy finished, so she was “clearly refractory,” he said. “Our data … Treated T-cells induce remissions in chemo-refractory B-cell lymphomasThe Oncology Report |
Age barrier falls for half-matched bone marrow transplantsThe Oncology ReportNo prior autologous BMT was allowed and post-BMT rituximab (Rituxan) was used in 55 of 126 patients with B-cell lymphoma. Patients in their 50s, 60s, and 70s had similar estim…